Strides Pharma Science Ltd

Strides Pharma Science Ltd announced that its flagship manufacturing facility in Bengaluru has received the Establishment Inspection Report (EIR) from the USFDA, signifying the successful closure of the inspection. The inspection, conducted from May 12-20, 2026, initially resulted in a Form 483 with five observations. Strides submitted a comprehensive response and implemented corrective actions, leading the USFDA to classify the outcome as Voluntary Action Indicated (VAI). This clearance reinforces the company's commitment to quality and its regulatory track record, supporting its supply of pharmaceutical products to global markets.

Strides Pharma Science Ltd reported a steady performance for Q1FY27, with revenue growing 13% year-on-year to ₹12,654 million. The Ex-US markets showed robust growth of 17% YoY, contributing ₹5,875 million, while the US business remained steady at ₹6,282 million, up 4% YoY. EBITDA increased by 5.4% YoY to ₹2,298 million, despite a ₹131 million impact from geopolitical disruptions on freight and operating costs. Operational PAT grew 8% YoY to ₹1,231 million. The company also unlocked ₹1,000 million in value through the divestment of its majority stake in Pivot Path, its captive GCC, while retaining meaningful participation. Net debt was reduced by ₹119 million, with Net Debt-to-EBITDA at 1.52x.

Strides Pharma Science Ltd announced the outcome of its Board Meeting held on July 31, 2026. The Board approved the Unaudited Financial Results (Consolidated and Standalone) for the quarter ended June 30, 2026. The financial results, along with the Limited Review Report from statutory auditors B S R & Co. LLP, were presented. The meeting commenced at 10:30 hrs IST and concluded at 12:30 hrs IST. The company will make this information available on its website.

Strides Pharma Science Ltd has announced that its Board of Directors will convene on July 31, 2026. The primary agenda item is to consider and approve the unaudited financial results for the quarter ended June 30, 2026, on both standalone and consolidated bases. Additionally, the company will address other business matters. In line with the company's insider trading policy, the trading window for designated persons will remain closed from July 1, 2026, until 48 hours after the financial results are declared. The company's website will also host this information.

Strides Pharma Science Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year ended March 31, 2026. The report, filed as per SEBI regulations, details the company's corporate identity, operational structure, and market presence. It covers standalone financial disclosures and consolidated other disclosures for Strides and its wholly-owned Indian subsidiary, Arcolab. The company operates in the manufacturing of pharmaceuticals, with 100% turnover from this segment. Strides serves a global market, with exports contributing 90.66% to its standalone turnover. The report also outlines employee and worker statistics as of FY26, with a total of 2,810 employees and 2,584 workers.

Strides Pharma Science Ltd has announced that its 35th Annual General Meeting (AGM) will be held on Friday, August 14, 2026, at 12:15 hrs IST. The meeting will be conducted through Video Conference/Other Audio-Visual Means (VC/OAVM). The company will also be presenting its Annual Report for FY2025-26, including the Business Responsibility and Sustainability Report. Key dates for shareholders include a cut-off date of August 7, 2026, for e-voting eligibility, with the e-voting period running from August 10 to August 13, 2026. The record date for dividend is July 31, 2026. The AGM will cover ordinary business, including the adoption of the Audited Financial Statements for FY2025-26.

Strides Pharma Science Ltd has announced its 35th Annual General Meeting (AGM) will be held on Friday, August 14, 2026, at 12:15 hrs IST. The meeting will be conducted through Video Conference/Other Audio-Visual Means (VC/OAVM) in compliance with the Companies Act, 2013, and SEBI Listing Regulations. The Annual Report for FY 2025-26, including the Business Responsibility and Sustainability Report, is being sent electronically to shareholders. Key dates include a cut-off for e-voting eligibility on August 7, 2026, with e-voting open from August 10 to August 13, 2026. The record date for dividend is July 31, 2026. The AGM will transact ordinary business, including the adoption of audited financial statements for the fiscal year ended March 31, 2026.

Strides Pharma Science Ltd has announced Friday, July 31, 2026, as the record date for determining shareholder entitlement to the final dividend for the financial year ended March 31, 2026. The company's Board of Directors had previously recommended a final dividend of ₹5 per equity share (50%). This dividend is subject to shareholder approval at the upcoming 35th Annual General Meeting (AGM), scheduled for Friday, August 14, 2026. The dividend, if approved, will be paid within 30 days of declaration, subject to applicable taxes.

Strides Pharma Science Ltd has successfully completed the transaction for its partnership with Ascent Capital concerning Pivot Path. The deal involved selling a majority stake in Pivot Path to a consortium led by Ascent Capital and co-investor Vintage Classic for approximately ₹1,000 million. Strides has received ₹750 million upfront, with the remaining ₹250 million due on the first anniversary of the closing date. Following this transaction, Pivot Path is no longer a wholly-owned subsidiary and will be classified as an associate company from July 1, 2026.

Strides Pharma Science Ltd. has announced a strategic investment by Ascent Capital and Vintage Classic in its subsidiary, Pivot Path Private Limited. The transaction values Pivot Path at approximately ₹2,300 million post-money, allowing Strides to realize around ₹1,000 million while retaining a 20% stake. Additionally, Pivot Path will receive ₹500 million in primary capital to fuel its growth and technology investments. This move aligns with Strides' strategy to unlock value from high-potential businesses. Pivot Path, which originated from Strides' Global Capability Centre, offers services in life sciences consulting, digital transformation, and technology. For FY26, the carved-out business reported revenue of ₹1,447 million and EBITDA of ₹169 million. Following the transaction, Pivot Path will be reclassified as an Associate of Strides Pharma Science Ltd.